RecruitingNCT07552285

The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center


Sponsor

The First Affiliated Hospital of Soochow University

Enrollment

300 participants

Start Date

May 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC,OGSE,CEST,IVIM,etc.The main question it aims to answer is: Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.


Eligibility

Sex: MALEMin Age: 20 YearsMax Age: 90 Years

Inclusion Criteria3

  • Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels;
  • Patients with no prior history of other tumors;
  • Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates.

Exclusion Criteria3

  • The patient has a history of malignant tumors and has received corresponding treatment;
  • Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.;
  • Patients who have previously undergone radical prostatectomy for prostate cancer.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERobservational study

The researchers will conduct observations, collect data and conduct follow-ups on the participants, but will not actively alter their treatment or health conditions.


Locations(1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07552285


Related Trials